NancyBDavisMD

Oncology • Nashville, TN

Genitourinary Oncology

Sr. Prin. Scientist, Clinical Research, Merck, Sharp & Dohme, Inc

Join to view full profile

Dr. Davis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davis' full profile

Already have an account?

Office
3601 Pierce Ave
Nashville, TN 37232
Phone+1 615-936-2000

Summary

I am board certified in Medical Oncology and specialize in the treatment of genitourinary cancers. I believe strongly in a multidisciplinary approach to management as well as involving patients in decisions about their care.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2000 - 2003
University of ChicagoResidency, Internal Medicine, 1997 - 2000
McGovern Medical School at UTHealthClass of 1997

Certifications & Licensure

TN State Medical License 2018 - 2027
GA State Medical License 2021 - 2025
AL State Medical License 2020 - 2023
WI State Medical License 2003 - 2023
IL State Medical License 1997 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Start of enrollment: 2018 Nov 06
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

24 citations
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman
Biomarker Research. 2021-11-03
11 citations
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outc...
Yu-Wei Chen, Matthew D Tucker, Landon C Brown, Hesham A Yasin, Kristin K Ancell
Cancers. 2022-08-07
39 citations
Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data
Anna R Smither, Michael L. Guralnick, Nancy B. Davis, William A. See
BMC Urology. 2007-02-05

Authored Content

What’s New in GU Malignancy? Update from the 2019 ASCO MeetingJune 2019

Press Mentions

Erlanger Welcomes Dr. Sandeep Rajan as Medical Director of Erlanger Oncology and HematologyJuly 19th, 2021
AUA 2019: Management Paradigms for Advanced nccRCC in the Modern EraMay 5th, 2019

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Member
American Society of Clinical Oncology - ASCO
Member
American Medical Association - AMA
Member
American Urological Association - AUA
Member
Society of Urologic Oncology
Member

Industry Relationships

IDMC Chair, Janssen SunRise Trials2020 - Present